



Insight

An ethical framework to assess covert consciousness

The potential for cognitive motor dissociation in patients who are behaviourally unresponsive after a severe brain injury poses profound ethical challenges. An international study revealed that one in four patients who appear unresponsive to verbal commands is capable of doing cognitive tasks detected through functional MRI or EEG (ie, has cognitive motor dissociation). Cognitive motor dissociation can be considered a subset of covert consciousness—that is, preserved consciousness that evades routine bedside detection.² Current task-based functional MRI and EEG tests are insensitive, because they are tailored to patients who can follow cognitively demanding instructions. Given the global burden of brain injury, the potential widespread prevalence of covert consciousness is likely to become a public health issue. Access to technologies to detect covert consciousness and to enhance prognostication remain out of reach for most patients worldwide. These circumstances introduce unprecedented questions. What obligations exist to detect covert consciousness and democratise access to neurotechnologies? What values and principles ought to guide the development and deployment of neurotechnologies for responsible assessments of consciousness and the prediction of recovery? Here, we describe an aspirational framework, co-designed by specialists in disorders of consciousness, clinical care, neurotechnology, and neuroethics. Our framework is not a definitive guide, but a starting point for collective deliberation, acknowledging the resource-limited environments in which medicine is practised. The obstacles to achieving these goals vary by country, necessitating approaches tailored to specific local conditions.

Insofar as consciousness grounds the possibility of subjective experience and self-expression (as Immanuel Kant designated “*the essential condition of all logical forms of cognitions*”), society at large has a vested interest in discovering its presence and neuronal substrate. Individuals with disorders of consciousness are at heightened risk of undertreatment, goal-discordant care, and marginalisation. Investments in research and infrastructure are therefore needed to democratise the implementation of, and access to, covert consciousness testing to ensure that patients who stand to benefit most from these techniques can equitably access them, and that these innovations do not remain siloed at their source. In tandem, educational initiatives involving caregivers, patient advocates, policymakers, health insurers, and other stakeholders are necessary to inform the public about the implications of covert consciousness. These efforts should seek societal input on whether and how to consider covert consciousness when determining

approaches to care. Such multi-stakeholder dialogue can help shape policies that reflect diverse ethical considerations, societal values, and the evolving scientific understanding of coma and consciousness.

In the international study, the detection of cognitive motor dissociation across sites was not uniformly one in four, but ranged from 2% to 45% of patients in the different centres—a discrepancy unlikely to be explained solely by the different populations. Furthermore, a high false-negative proportion of 62% was observed across sites in patients who were overtly conscious, underscoring the poor performance of task-based functional MRI or EEG for detecting consciousness. Many patients are unable to demonstrate command-following through functional MRI or EEG, and even healthy individuals can have difficulties with such tasks. Standard operating procedures should therefore be established to promote consistency in stimulation paradigms, analysis methods, and the interpretation of results. Reproducibility across different settings, including resource-limited environments, is essential. Furthermore, complementary techniques for detecting consciousness that are not cognitively demanding are warranted. These techniques might include passive paradigms, such as EEG or neuroimaging assessment of cognitive processing, or the use of transcranial magnetic stimulation combined with EEG that probes brain complexity, with the ultimate goal of establishing a toolkit of complementary assessments. Empirical neuroethics inquiry, including examining the experiences of patients who have emerged from covert to overt consciousness, should be embedded in future research efforts to clarify its phenomenology and normative dimensions, elements that have been conspicuously overlooked so far.

Given the relatively high incidence of covert consciousness among behaviourally unresponsive patients, it is incumbent upon clinicians to adopt a default assumption that any unresponsive patient might still possess residual consciousness. This precautionary premise should inform bedside manner and overall approaches to patient care. For clinicians involved in assessing consciousness, a standardised, tiered assessment strategy is appropriate for patients in facilities with access to the necessary infrastructure. This strategy should begin with serial standardised neurobehavioural assessments. If neurobehavioural assessments indicate a positive result (ie, overt signs of consciousness), no further testing might be necessary. However, if the assessments yield a negative result, clinicians should consider more sophisticated testing. The next step in a tiered approach should include testing for covert consciousness, which can include task-based EEG or functional MRI. If unavailable, at a minimum, resting-

For the **international study** see *New Engl J Med* 2024; **391**: 598–608

For more on **covert consciousness** see *NeuroRehabilitation* 2024; **54**: 23–42

For more on **Immanuel Kant** see Kant I [Young JM, ed]. *Lectures on Logic*, Cambridge University Press, 2004

For more on **brain complexity** see *Neurocrit Care* 2023; **38**: 584–90

For more on **neurobehavioural assessments** see *Neurology* 2018; **91**: 450–60

For more on **counselling** see *Neurocrit Care* 2024; **40**: 865–78

For the **European guidelines** see *Eur J Neurol* 2020; **27**: 741–56

For more on **candidate strategies** see *Neurocrit Care* 2024; **41**: 345–56

For more on **diagnostic accuracy of vegetative state** see *BMC Neurology* 2009; **9**: 35

For more on **prognostic implications** see *J Neurotrauma* 2012; **29**: 59–65

For more on **outcome** see *New Engl J Med* 2019; **380**: 2497–505

For more on **pharmacological approaches** see *Lancet Neurol* 2019; **18**: 600–14

For more on **palliative care** see *Neurology* 2018; **91**: 471–75

For more on **brain-computer interfaces** see *Neurocrit Care* 2024; **41**: 129–45

For **authors' affiliations and conflicts of interest** see *Online* for appendix

state EEG should be obtained. Results of testing should be carefully framed and responsibly shared with carers and families, by use of visual aids to enhance communication when possible, and pre-test and post-test counselling. Recognising that states of consciousness can fluctuate, repeated assessments, particularly with EEG due to its relative ease of administration, might be warranted. In line with European guidelines, a patient should be classified according to the highest level of consciousness detected through any test, implying that, when testing has not been exhausted, the evaluation remains incomplete. Disparate approaches are offered by US and UK guidelines, and opportunities for harmonisation exist. For patients in settings without advanced testing, clinicians should consider transferring patients to facilities that offer bundled testing. In some cases, screening tests like resting-state EEG might be indicated. Hub-and-spoke model systems and open-sourcing of testing pipelines are candidate strategies that could be leveraged to enhance global accessibility of advanced techniques. The high costs of advanced technologies, the need for specialists to process and interpret results, lack of health provision in many parts of the world, and the inherent uniqueness of each patient limit uniform access to testing. Moreover, despite that up to 40% of patients diagnosed by medical consensus as being in a vegetative state are actually in a minimally conscious state, with significant prognostic implications, many countries still lack the basic infrastructure to routinely mandate such evaluations. This situation underscores a need for foundational infrastructure and education.

Communicating the diagnosis of covert consciousness requires a nuanced approach that emphasises diagnostic humility. It is important to convey that a person can be conscious, that is, have subjective experiences, even in the absence of external signs of awareness. Technologies such as EEG and functional MRI can reveal brain activity indicative of consciousness, but these

tools have limitations, and the absence of signs of covert consciousness does not necessarily imply the absence of consciousness. Conversely, their presence can provide hope for future recovery, though outcome remains a complex and uncertain area of study. Further research is needed to elucidate optimal approaches to interpret composite test results and reconcile discordant results.

The detection of covert consciousness should inform patient care in ways that prioritise potential for recovery, and support liminal capacities and the restoration of self-expression. Management should also involve optimisation of pharmacological approaches to promoting wakefulness and awareness. While the presence of command-following or preserved brain complexity might warrant a search for subtle motor output or obstacles to self-expression, it is appropriate to remain agnostic about prioritising patients based solely on advanced technology, especially as the sensitivity and specificity of such tests are not enough. Advance care planning should prompt proactive consideration of covert consciousness. Care directives should reflect the possibility of covert consciousness and guide interventions in alignment with patients' preferences and quality-of-life considerations. Proactive attention to potential sources of pain and discomfort is therefore essential and can be optimally addressed in consultation with palliative care specialists.

As neurotechnologies evolve, their development and deployment must be guided by values and principles that ensure responsible design and ethical use. Key considerations include accessibility, feasibility, reproducibility, sensitivity, specificity, relative risk, and cost-effectiveness. These considerations should be balanced with the practicalities of bedside testing and the need for technologies that are both easy to use and economically viable. In the context of brain-computer interfaces, which hold promise for refining assessment and management of covert consciousness, it is important to consider the trade-offs between invasive and non-invasive approaches.

The discovery of covert consciousness and its under-diagnosis requires a re-evaluation of current practises. Reconciling the ethical, clinical, and societal challenges raised by these discoveries requires an approach that proactively incorporates the perspectives from clinicians, researchers, ethicists, patient advocates, and policymakers (figure). As knowledge on consciousness continues to increase, so too must approaches to its detection, and to prognosis and management, and communication to carers and the public. From recognition of covert consciousness thus follows a moral obligation to foster the development of accessible approaches to testing for all patients affected.

Michael J Young, Christof Koch, Jan Claassen, David Fischer, Charlène Aubinet, Olivia Gosseries, Daniel Kondziella, Mario Rosanova, Simone Sarasso, Silvia Casarotto, Marcello Massimini, Brian L Edlow




Figure: A framework for expanding testing of covert consciousness worldwide, based on aligning ethical principles with research and clinical practice

Supplementary appendix

This appendix formed part of the original submission and has been peer reviewed.
We post it as supplied by the authors.

Supplement to: Young MJ, Koch C, Claassen J, et al. An ethical framework to assess covert consciousness. *Lancet Neurol* 2025; **24**: 195–96.

Authors' Affiliations

Michael J. Young¹, Christof Koch^{2,3}, Jan Claassen⁴, David Fischer⁵, Charlène Aubinet⁶, Olivia Gosseries⁶, Daniel Kondziella^{7,8}, Mario Rosanova⁹, Simone Sarasso⁹, Silvia Casarotto^{9,10}, Marcello Massimini^{9,10}, Brian L. Edlow¹

¹ Center for Neurotechnology and Neurorecovery, Massachusetts General Hospital, Boston, MA, USA; ² Allen Institute, Seattle, WA, USA; ³ Tiny Blue Dot Foundation, Santa Monica, CA, USA; ⁴ Disorders of Consciousness Laboratory, Columbia University, New York, NY, USA; ⁵ Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; ⁶ Coma Science Group, GIGA-Consciousness, University of Liège & Centre du Cerveau, University Hospital of Liège, Belgium; ⁷ Department of Neurology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; ⁸ Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark; ⁹ Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy; ¹⁰ IRCCS Fondazione Don Carlo Gnocchi ONLUS, Milan, Italy

Acknowledgements/Disclosures

This manuscript was conceived at a workshop on “Disorders of Consciousness”, organized by the *Neuroscience School of Advanced Studies* in Crans-Montana, Switzerland. MJY has received funding from the NIH BRAIN Initiative, NIH Common Fund (Bridge2AI CHoRUS), and American Academy of Neurology (Palatucci Advocacy Award). BLE has received funding from NIH National Institute of Neurological Disorders and Stroke (R01NS138257), NIH Director's Office (DP2HD101400), the Chen Institute MGH Research Scholar Award, and the MIT/MGH Brain Arousal State Control Innovation Center (BASCIC) project. JC has received funding from the NIH National Institute of Neurological Disorders and Stroke (NS106014; R03NS112760) and is a minority shareholder at iCE Neurosystems. CK holds an executive position, and CK and MM have a financial interest in Intrinsic Powers, Inc. OG is supported by the University and University Hospital of Liège, the Belgian National Fund for Scientific Research (FRS-FNRS), and the ERA-Net FLAG-ERA JTC2021. CA is a research fellow and OG is a research associate at FRS-FNRS. DK has received funding from the Lundbeck Foundation (LF-R349-2020-658) and the Novo Nordisk Foundation (NNF21OC0067769). MR has received funding from Fondazione Regionale per la Ricerca Biomedica (Regione Lombardia), Project ERAPERMED2019–101, GA 779282. MM is supported by the Canadian Institute for Advanced Research (CIFAR) and by the European Research Council (ERC-2022-SYG-101071900- NEMESIS). MR, SC and SS are advisors of Intrinsic Powers, Inc. DF is supported by the NIH National Institute of Neurological Disorders and Stroke (R25NS06574309), the American Academy of Neurology (Clinical Research Training Scholarship), the Neurocritical Care Society (Research Training Fellowship), the University of Pennsylvania Center for Clinical Epidemiology and Biostatistics (Research Program Award).

References

1. Bodien YG, Allanson J, Cardone P, et al. Cognitive Motor Dissociation in Disorders of Consciousness. *New England Journal of Medicine* 2024; **391**(7): 598-608.
2. Young MJ, Edlow BL, Bodien YG. Covert consciousness. *NeuroRehabilitation* 2024; **54**(1): 23-42.
3. Maas AI, Menon DK, Manley GT, et al. Traumatic brain injury: progress and challenges in prevention, clinical care, and research. *The Lancet Neurology* 2022; **21**(11): 1004-60.
4. Fischer D, Edlow BL. Coma prognostication after acute brain injury: a review. *JAMA neurology* 2024.
5. Kant I, Translated by Young JM. *Lectures on Logic*: Cambridge University Press; 2004.
6. Edlow BL, Fecchio M, Bodien YG, et al. Measuring consciousness in the intensive care unit. *Neurocritical Care* 2023; **38**(3): 584-90.
7. Giacino J, Katz D, Schiff N, et al. Practice guideline update recommendations summary: Disorders of consciousness: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology; the American Congress of Rehabilitation Medicine; and the National Institute on Disability, Independent Living, and Rehabilitation Research. *Neurology* 2018; **91**(10): 450-60.
8. Kondziella D, Bender A, Diserens K, et al. European Academy of Neurology guideline on the diagnosis of coma and other disorders of consciousness. *European journal of neurology* 2020; **27**(5): 741-56.
9. Young MJ, Kazazian K, Fischer D, Lissak IA, Bodien YG, Edlow BL. Disclosing results of tests for covert consciousness: A framework for ethical translation. *Neurocritical Care* 2024: 1-14.
10. Rubin MA, Lewis A, Creutzfeldt CJ, et al. Equity in clinical care and research involving persons with disorders of consciousness. *Neurocritical Care* 2024: 1-12.
11. Schnakers C, Vanhaudenhuyse A, Giacino J, et al. Diagnostic accuracy of the vegetative and minimally conscious state: clinical consensus versus standardized neurobehavioral assessment. *BMC neurology* 2009; **9**: 1-5.
12. Nakase-Richardson R, Whyte J, Giacino JT, et al. Longitudinal outcome of patients with disordered consciousness in the NIDRR TBI Model Systems Programs. *Journal of Neurotrauma* 2012; **29**(1): 59-65.
13. Claassen J, Doyle K, Matory A, et al. Detection of brain activation in unresponsive patients with acute brain injury. *New England Journal of Medicine* 2019; **380**(26): 2497-505.
14. Thibaut A, Schiff N, Giacino J, Laureys S, Gosseries O. Therapeutic interventions in patients with prolonged disorders of consciousness. *The Lancet Neurology* 2019; **18**(6): 600-14.
15. Schiff ND, Diring M, Diserens K, et al. Brain-Computer Interfaces for Communication in Patients with Disorders of Consciousness: A Gap Analysis and Scientific Roadmap. *Neurocritical care* 2024: 1-17.
16. Fins JJ, Bernat JL. Ethical, palliative, and policy considerations in disorders of consciousness. *Neurology* 2018; **91**(10): 471-5.